Literature DB >> 11488782

Tacrolimus/cerivastatin interaction study in liver transplant recipients.

W Mück, D A Neal, O Boix, B Voith, R Hasan, G J Alexander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11488782      PMCID： PMC2014527     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  16 in total

1.  Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient.

Authors:  D Capone; A Gentile; P Imperatore; G Palmiero; V Basile
Journal:  Ann Pharmacother       Date:  1999-10       Impact factor: 3.154

2.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.

Authors:  K Wenke; B Meiser; J Thiery; D Nagel; W von Scheidt; G Steinbeck; D Seidel; B Reichart
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

3.  Interaction between tacrolimus and erythromycin.

Authors:  C Jensen; M Jordan; R Shapiro; V Scantlebury; T Hakala; J Fung; T Starzl; R Venkataramanan
Journal:  Lancet       Date:  1994-09-17       Impact factor: 79.321

4.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.

Authors:  W Mück; I Mai; L Fritsche; K Ochmann; G Rohde; S Unger; A Johne; S Bauer; K Budde; I Roots; H H Neumayer; J Kuhlmann
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

5.  LC separation and induced fluorometric detection of rivastatin in blood plasma.

Authors:  G J Krol; G W Beck; W Ritter; J T Lettieri
Journal:  J Pharm Biomed Anal       Date:  1993 Nov-Dec       Impact factor: 3.935

6.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.

Authors:  L C Floren; I Bekersky; L Z Benet; Q Mekki; D Dressler; J W Lee; J P Roberts; M F Hebert
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

7.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.

Authors:  C Olbricht; C Wanner; T Eisenhauer; V Kliem; R Doll; M Boddaert; P O'Grady; M Krekler; B Mangold; U Christians
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

8.  HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.

Authors:  P F Smith; R S Eydelloth; S J Grossman; R J Stubbs; M S Schwartz; J I Germershausen; K P Vyas; P H Kari; J S MacDonald
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

9.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

Authors:  S Katznelson; A H Wilkinson; J A Kobashigawa; X M Wang; D Chia; M Ozawa; H P Zhong; M Hirata; A H Cohen; P I Teraski
Journal:  Transplantation       Date:  1996-05-27       Impact factor: 4.939

10.  Effect of pravastatin on outcomes after cardiac transplantation.

Authors:  J A Kobashigawa; S Katznelson; H Laks; J A Johnson; L Yeatman; X M Wang; D Chia; P I Terasaki; A Sabad; G A Cogert
Journal:  N Engl J Med       Date:  1995-09-07       Impact factor: 91.245
View more
  6 in total

Review 1.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.

Authors:  Lutz Renders; Christian S Haas; Jan Liebelt; Martin Oberbarnscheidt; Harald O Schöcklmann; Ulrich Kunzendorf
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

3.  Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

Review 4.  Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

Authors:  Giuseppina Pisano; Anna L Fracanzani; Lucio Caccamo; Maria F Donato; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

Review 5.  Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation.

Authors:  Marcio W Lauria; Antonio Ribeiro-Oliveira
Journal:  Clin Diabetes Endocrinol       Date:  2016-07-15

6.  Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery.

Authors:  Elias Khajeh; Arash Dooghaie Moghadam; Pegah Eslami; Sadeq Ali-Hasan-Al-Saegh; Ali Ramouz; Saeed Shafiei; Omid Ghamarnejad; Sepehr Abbasi Dezfouli; Christian Rupp; Christoph Springfeld; Carlos Carvalho; Pascal Probst; Seyed Mostafa Mousavizadeh; Arianeb Mehrabi
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.